Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Standard Biotools (LAB) Preferred Stock Liabilities (2022 - 2023)

Standard Biotools has reported Preferred Stock Liabilities over the past 3 years, most recently at $311.3 million for Q4 2023.

Quarterly Preferred Stock Liabilities changed 0.0% to $311.3 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $311.3 million through Dec 2023, changed 0.0% year-over-year, with the annual reading at $311.3 million for FY2023, 0.0% changed from the prior year.
Preferred Stock Liabilities was $311.3 million for Q4 2023 at Standard Biotools, roughly flat from $311.3 million in the prior quarter.
Over five years, Preferred Stock Liabilities peaked at $311.3 million in Q2 2022 and troughed at $311.3 million in Q2 2022.